Dr. Jakubowiak on Phase I Daratumumab Regimens in Newly Diagnosed Multiple Myeloma
June 12th 2017Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.
Read More
Dr. Jakubowiak Discusses the Toxicity Profile of Panobinostat in the PANORAMA Trial
June 17th 2014Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Read More